Neurogene Inc. (NASDAQ:NGNE – Get Free Report) has earned an average recommendation of “Buy” from the nine analysts that are currently covering the firm, Marketbeat.com reports. Eight analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $51.00.
Separately, HC Wainwright cut their price objective on shares of Neurogene from $51.00 to $49.00 and set a “buy” rating on the stock in a report on Monday, August 12th.
Read Our Latest Analysis on NGNE
Neurogene Stock Up 0.4 %
Neurogene (NASDAQ:NGNE – Get Free Report) last issued its earnings results on Friday, August 9th. The company reported ($1.09) earnings per share for the quarter, missing the consensus estimate of ($1.02) by ($0.07). The firm had revenue of $0.93 million during the quarter. Equities research analysts anticipate that Neurogene will post -4.47 EPS for the current fiscal year.
Institutional Inflows and Outflows
Several institutional investors have recently added to or reduced their stakes in NGNE. Quest Partners LLC acquired a new stake in shares of Neurogene in the second quarter valued at approximately $55,000. SG Americas Securities LLC purchased a new stake in Neurogene in the 1st quarter valued at $120,000. Rhumbline Advisers acquired a new stake in Neurogene during the 2nd quarter worth $491,000. Avoro Capital Advisors LLC purchased a new position in Neurogene during the 2nd quarter worth $802,000. Finally, Bank of New York Mellon Corp acquired a new position in Neurogene in the second quarter valued at $1,107,000. Institutional investors and hedge funds own 52.37% of the company’s stock.
Neurogene Company Profile
Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.
Featured Stories
- Five stocks we like better than Neurogene
- What is a Bond Market Holiday? How to Invest and Trade
- Real Estate Sector Outperforms: 3 Stocks to Gain Exposure
- Top Stocks Investing in 5G Technology
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- How is Compound Interest Calculated?
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
Receive News & Ratings for Neurogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurogene and related companies with MarketBeat.com's FREE daily email newsletter.